Filing Flows › Aytu Biopharma (AYTU) › Q4 FY26 › vs Q3 FY26
Aytu Biopharma (AYTU) Q4 FY26 vs Q3 FY26 (quarter over quarter)
Aytu Biopharma's revenue rose $3.7M (+30%) from $12.4M in Q3 FY26 to $16.1M in Q4 FY26.
Aytu Biopharma, Q4 FY26: revenue $16.1M (+6% year over year), operating margin -4.8%, net loss $15K, operating cash flow $4.4M. The chart draws each line against Q3 FY26, the increases inside each band.
Margins
| Q4 FY26 | Q3 FY26 | Change | |
|---|---|---|---|
| Free cash flow margin | 27.3% | -33.7% | +61.0 pts |
Every line
| Line | Q4 FY26 | Q3 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $16.1M | $12.4M | $3.7M | +30% |
| Other income, net | $773K | −$1.5M | $2.3M | — |
| Net loss | $15K | $5.6M | −$5.6M | -100% |
| Costs & expenses | $16.9M | $18.0M | −$1.1M | -6% |
| Operating costs | $16.9M | $16.5M | $408K | +2% |
| Income tax | $11K | $10K | $1K | +10% |
| Cost of revenue | $5.7M | $4.8M | $885K | +18% |
| Sales & marketing | $6.1M | $5.9M | $191K | +3% |
| General & admin | $4.3M | $5.0M | −$668K | -13% |
| Other operating costs | $761K | $761K | $0 | 0% |
| Operating cash sources | $4.4M | $1.4M | $3.0M | +208% |
| Depreciation & amortization | $1.1M | $1.1M | $0 | 0% |
| Share-based compensation | $146K | $148K | −$2K | -1% |
| Working capital & other | $3.2M | $167K | $3.0M | 19× |
| Net loss absorbed | $15K | $5.6M | −$5.6M | -100% |
| Operating cash flow | $4.4M | −$4.2M | $8.6M | — |
| Free cash flow (OCF − capex) | $4.4M | −$4.2M | $8.6M | — |
| Capital expenditures | $12K | $0 | $12K | — |
Questions
How much did Aytu Biopharma's revenue grow quarter over quarter in Q4 FY26?
Aytu Biopharma's revenue rose $3.7M (+30%) from $12.4M in Q3 FY26 to $16.1M in Q4 FY26.